ALBUQUERQUE, N.M., April 17 /PRNewswire-FirstCall/ -- Biomoda, Inc. , Albuquerque, NM www.biomoda.com, maker of patented early lung cancer detection testing and other cancer diagnostic technology, has been accepted for representation by Synergestic Marketing www.4synergestic.com, which among other clients has represented Fujitsu FCPA-Medical MO Ultrasound Recording; Bell and Howell-Kodak Service; American Airlines-Wireless Logistics; and five Hitachi Units, including Medical Records Tech and MRI Imaging.
John Cousins, President of Biomoda, which completed negotiations with Synergestic, stated: “In conjunction with our product commercialization goals, we are focusing on developing revenues in the near term, and look to Synergestic to accelerate licensing development and sales relationships with customers domestically and worldwide. Synergestic brings to the table the ability to achieve our goal to generate sales and rapidly grow our top line.” Biomoda trades on NASDAQ’s OTC Bulletin Board: ticker symbol “BMOD.”
Synergestic, founded in 1990, has an extraordinary track record and Mark Lutvak, Synergestic’s President, said “We see Biomoda, Inc. as joining the ranks of some of our very successful world class clients. We have been impressed with Biomoda’s relationships and progress, including Biomoda’s joint work with the world respected Mayo Clinic. Biomoda.”
Mayo Clinic (Rochester, Minnesota) and Biomoda, Inc. (Albuquerque NM) have agreed to jointly conduct a broad validation study of Biomoda’s patented technology, a non-invasive cytology based lung cancer diagnostic assay.
Biomoda’s technology is based on a patented porphyrin application that preferentially binds to cancerous or aberrant cells extracted from lung sputum samples. Cancerous cells glow red under fluorescent light to allow detection under a microscope. The patented technology is designed for cancer screening at an early stage of large populations at a very affordable cost.
Lung cancer claims more lives than any other cancer. The expected 5-year survival rate for all patients combined in whom lung cancer is diagnosed is 15 percent and by contrast, the 5-year survival rate for cases detected when the disease is still localized is 50 percent. At the present time, only 16 percent of lung cancer cases are diagnosed at this early stage.
“Safe Harbor” Statement: This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are naturally subject to uncertainty and changes in circumstances. Actual results may vary materially from expectations contained herein. Biomoda is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT:
Biomoda, Inc., Albuquerque
John Cousins, 505-821-0875
Biomoda, Inc.
CONTACT: John Cousins of Biomoda, Inc., +1-505-821-0875
